

Wilson S Meng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8414164/publications.pdf>

Version: 2024-02-01

41
papers

1,122
citations

471509

17
h-index

395702

33
g-index

42
all docs

42
docs citations

42
times ranked

1389
citing authors

#	ARTICLE	IF	CITATIONS
1	T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human $\hat{\pm}$ Fetoprotein. <i>Journal of Immunology</i> , 2001, 166, 5300-5308.	0.8	131
2	Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2013, 24, 398-416.	3.5	111
3	Retaining Antibodies in Tumors with a Self-Assembling Injectable System. <i>Molecular Pharmaceutics</i> , 2013, 10, 1035-1044.	4.6	86
4	Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. <i>Journal of Pharmaceutical Innovation</i> , 2014, 9, 158-173.	2.4	85
5	Coassembly of amphiphilic peptide EAK16-II with histidinylated analogues and implications for functionalization of β -sheet fibrils in vivo. <i>Biomaterials</i> , 2014, 35, 5196-5205.	11.4	69
6	Protein aggregation and immunogenicity of biotherapeutics. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119523.	5.2	64
7	Antibody-functionalized peptidic membranes for neutralization of allogeneic skin antigen-presenting cells. <i>Acta Biomaterialia</i> , 2014, 10, 4759-4767.	8.3	61
8	Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation. <i>Clinical Immunology</i> , 2015, 160, 103-123.	3.2	58
9	Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human $\hat{\pm}$ -fetoprotein. <i>Molecular Immunology</i> , 2000, 37, 943-950.	2.2	51
10	A peptide-based material platform for displaying antibodies to engage T cells. <i>Biomaterials</i> , 2011, 32, 249-257.	11.4	47
11	Bioengineering mini functional thymic units with EAK16-II/EAKIIH6 self-assembling hydrogel. <i>Clinical Immunology</i> , 2015, 160, 82-89.	3.2	33
12	Advances in immunotherapy of type I diabetes. <i>Advanced Drug Delivery Reviews</i> , 2019, 139, 83-91.	13.7	32
13	Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. <i>Molecular Immunology</i> , 2004, 41, 741-749.	2.2	27
14	Engineering Fluorogen Activating Proteins into Self-Assembling Materials. <i>Bioconjugate Chemistry</i> , 2013, 24, 803-810.	3.6	25
15	Water dynamics at the binding interface of four different HLA-A2 peptide complexes. <i>International Immunology</i> , 2000, 12, 949-957.	4.0	24
16	A cationic peptide consists of ornithine and histidine repeats augments gene transfer in dendritic cells. <i>Molecular Immunology</i> , 2003, 40, 483-490.	2.2	23
17	Polymeric microspheres as stabilizing anchors for oligonucleotide delivery to dendritic cells. <i>Biomaterials</i> , 2005, 26, 6754-6761.	11.4	22
18	Activation of antigen-presenting cells by DNA delivery vectors. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1019-1028.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Local retention of antibodies in vivo with an injectable film embedded with a fluorogen-activating protein. <i>Journal of Controlled Release</i> , 2016, 230, 1-12.	9.9	16
20	Reducing <i>Escherichia coli</i> growth on a composite biomaterial by a surface immobilized antimicrobial peptide. <i>Materials Science and Engineering C</i> , 2016, 65, 126-134.	7.3	16
21	Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation. <i>Frontiers in Immunology</i> , 2021, 12, 586220.	4.8	16
22	A genetically engineered Fc-binding amphiphilic polypeptide for congregating antibodies in vivo. <i>Acta Biomaterialia</i> , 2019, 88, 211-223.	8.3	14
23	Surface modification of PLGA nanoparticles to deliver nitric oxide to inhibit <i>Escherichia coli</i> growth. <i>Applied Surface Science</i> , 2017, 401, 162-171.	6.1	11
24	Expansion of Foxp3-expressing regulatory T cells in vitro by dendritic cells modified with polymeric particles carrying a plasmid encoding interleukin-10. <i>Biomaterials</i> , 2008, 29, 1250-1261.	11.4	10
25	Promoting 3-D Aggregation of FACS Purified Thymic Epithelial Cells with EAK 16-II/EAKIIIH6 Self-assembling Hydrogel. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	10
26	Antimicrobial Activity of Nitric Oxide-Releasing Ti-6Al-4V Metal Oxide. <i>Journal of Functional Biomaterials</i> , 2017, 8, 20.	4.4	10
27	Characterization of particles fabricated with poly(D,L-lactic-co-glycolic acid) and an ornithine-histidine peptide as carriers of oligodeoxynucleotide for delivery into primary dendritic cells. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2006, 17, 1389-1403.	3.5	9
28	Toward reducing biomaterial antigenic potential: a miniaturized Fc-binding domain for local deposition of antibodies. <i>Biomaterials Science</i> , 2019, 7, 760-772.	5.4	9
29	Rational design of peptide-based tumor vaccines. <i>Pharmaceutical Research</i> , 2002, 19, 926-932.	3.5	8
30	Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu. <i>Molecular Immunology</i> , 2007, 44, 322-331.	2.2	7
31	Characterization of Nickel-Decorated PLGA Particles Anchored with a His-tagged Polycation. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2009, 20, 1307-1320.	3.5	6
32	Experimental evidence for the presence of a water network at the peptide-MHC interface. <i>Immunology Letters</i> , 2000, 70, 139-141.	2.5	3
33	Nanotherapeutics for autoimmunity becomes mainstream. <i>Clinical Immunology</i> , 2015, 160, 1-2.	3.2	3
34	Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNF \pm Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. <i>PLoS ONE</i> , 2015, 10, e0135451.	2.5	3
35	A Bioinformatics Practicum to Develop Student Understanding of Immunological Rejection of Protein Drugs. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 147.	2.1	2
36	A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 338-345.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Immune Cells Activating Biotin-Decorated PLGA Protein Carrier. <i>Molecular Pharmaceutics</i> , 2022, 19, 2638-2650.	4.6	2
38	Developing Biotherapeutics in the New Decade. <i>Journal of Pharmaceutical Innovation</i> , 2020, 15, 201-201.	2.4	0
39	Chemically-Induced Cross-Linking of Peptidic Fibrils for Scaffolding Polymeric Particles and Macrophages. <i>Macromolecular Bioscience</i> , 2021, 21, e2000350.	4.1	0
40	Principles of Nanomedicine. , 2017, , 39-66.		0
41	Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma. <i>Frontiers in Drug Delivery</i> , 2022, 2, .	1.6	0